Neil is a healthcare innovation leader with over 30 years of experience bringing life-changing biotechnology products to market. With a clear focus on cultivating products that deliver value to patients, paired with an inspiring vision that nurtures an inclusive work culture – Neil has developed products and people that make a difference. Having served in multiple positions over 12 years at Roche Diagnostics, he started in the Molecular business, and most recently led their Sequencing business unit, where he grew the business both organically and inorganically by partnering with, growing and integrating multiple startups. While at Roche Molecular Diagnostics, Neil strategically drove the clinical evidence generation that established cobas HPV as the first molecular test to be approved by the FDA for primary screening of HPV for cervical cancer, making a difference in the lives of thousands of women. Prior to Roche, Neil held senior roles in both Europe and the US at Pall Medical Ltd., Novartis Diagnostics, and Gambro BCT. Neil holds a PhD in Marine Microbiology and an MS in Biology from Portsmouth University, UK as well as a BS in Biology from Nottingham Trent University, UK.
Guochun Liao brings over 15 years of experience leading and managing multi-discipline teams in large pharmaceutical and small biotechnology startup companies. Prior to founding IDbyDNA, he was the Vice President of Bioinformatics at Centrillion Biosciences. Before that, he was the Head of Computational Genomics and Research Biostatistics at Roche Pharmaceuticals Palo Alto site, where he was responsible for the data management and analysis for the pre-clinical and clinical projects covering a variety of disease biology and functional areas. Guochun has also served as a consulting professor at Stanford University School of Medicine. His scientific work is featured in many patents, peer reviewed publications and on the cover of scientific journals, including Science and Genome Research. Guochun holds a BS in Biophysics from the University of Science and Technology of China, and an MS in Computer Science, a Ph.D. in Genetics and an MBA from the University of California, Berkeley.
Robert Schlaberg is an Assistant Professor of Pathology at the University of Utah School of Medicine and a Medical Director at ARUP Laboratories. His research is focused on next-generation sequencing-based infectious disease diagnostics and is supported in part by the Bill & Melinda Gates Foundation. Robert co-developed Taxonomer, the metagenomics data analysis platform, utilized by IDbyDNA as its central technology. Robert received Medical degrees from the Julius-Maximilians-University in Wuerzburg, Germany and a Masters of Public Health from Columbia University where he also trained in clinical pathology and served as Chief Clinical Pathology Resident. Robert is a board certified Clinical Pathologist and Medical Microbiologist.
Mark Yandell is a recognized leader in the field of software development for comparative and functional genomics. He is a Professor of Human Genetics and H.A. & Edna Benning Presidential Endowed Chair at the University of Utah, serves as Director of the Bioinformatics program, and Co-director of the Utah Science Technology and Research Center for Genetic Discovery. In addition to developing essential algorithms for the Human Genome Project, Mark developed software at Celera Genomics used to analyze human, mouse, fruit fly, and mosquito genomes. Mark also serves as Technical Director of the Utah Genome Project, and Associate Director of the University of Utah Program in Personalized Health. Mark holds a PhD in Molecular, Cell & Developmental Biology from The University of Colorado, Boulder and completed his post-doctoral work in Computational Biology at Washington University, St. Louis.
Peter Bacas is a business development executive with experience leading IVD and medical device startup growth. Prior to joining IDbyDNA, he led the commercial and business development function at Lucira Health (LHDX), a leading at-home diagnostics company. He has industry-leading experience developing business models in multi-stakeholder markets launch strategies driven by value-add product positioning and cost-effective commercial growth. He received his BSE in Bioengineering from the University of Pennsylvania.
Ted Echemann is a business executive in the biotech industry with over 12 years’ experience commercializing novel technologies at start-ups and growth companies in both oncology and infectious disease. Prior to joining IDbyDNA, he led GTM strategies for Circulogene and Farcast Biosciences, through sales leadership and national account development. He has industry-leading experience navigating complex sales, negotiations, and multi-stakeholder KOL development. His patient-first approach drives his ability to build industry leading teams of impassioned consultants that successfully launch new products and grow market share. Ted believes every patient deserves the best technology and best care every time. He received his BS in Marketing from Southern Illinois University.
Dina Hannah is a Quality and Compliance professional with over 30 years in the clinical reference laboratory and biotech industries. Her experience includes leading corporate compliance, quality systems, corporate privacy, and information security teams in revolutionary and rapidly evolving regulatory and quality system environments. Prior to joining IDbyDNA, she served as Chief Compliance Officer for TriCore Reference Laboratories and as VP, Compliance and Quality for ARUP Laboratories. She began her laboratory sciences career as a certified medical technologist and specialist in blood banking and has nearly 20 years of laboratory compliance experience. Dina received an MBA with an emphasis in health care management from University of Phoenix, a BS in Clinical Laboratory Science from Brigham Young University and is a certified security and information privacy professional.
Chris Minunni brings over 10 years of legal, finance, and operations experience working with technology and life science companies in the Bay Area. He joins IDbyDNA from Bracket Computing, a venture-backed enterprise infrastructure and security software company, where he was Vice President of Business Operations and General Counsel. Previously he was a corporate attorney at Cooley LLP. He holds a JD from Columbia Law School and a BA from Cornell University.
Prof. dr. John W. A. Rossen has a 30-year history in molecular virology and microbiology, and more than 185 peer reviewed publications on this topic (H-index 39). He obtained a Master of Science in Molecular Cell Biology and in Virology (1991, Faculty of Biology, Utrecht University) and a PhD in (Molecular) Virology and Cell Biology on the topic: “Coronavirus – epithelial cell interaction” (1996, Faculty of Veterinary Medicine, Utrecht University). Since 2004, next to his fundamental research, he is actively involved in research in and molecular diagnostics of infectious diseases. As a Professor for Medical Microbiology, in particular Personalised Microbiology, at the University of Groningen he successfully implemented the use of next generation sequencing for routine clinical microbiology and infection prevention. With his research group “Personalised Microbiology” he focuses on implementing metagenomics and metatranscriptomics into clinical microbiology. He is the immediate past president of the ESCMID study group for genomic and molecular diagnostics (ESGMD). From the year 2020 he joined IDbyDNA to further set the standard for the identification and understanding of microorganisms and their role in human disease. Within his new role he will focus on Product Strategy (Europe) and on Research & Development and Product Development (Global). From March, 2020 he is appointed as Adjunct Professor at the Department of Pathology of the University of Utah School of Medicine.
Jun Wang brings over 19 years of leadership, management and R&D experience from large molecular diagnostics and biotech startup companies. He joins IDbyDNA from Sansure Biotech, a leading molecular diagnostic company in China, where he served as board member and chief technology officer. He also served as a distinguished professor at Central South University. Prior to these, Jun led research groups at Fluidigm Corporation and Roche Molecular Diagnostics. His scientific work is featured in over 50 peer-reviewed scientific publications and patents. Jun holds a PhD of biochemistry from University of Toronto and completed his post-doctoral work at Roche Pharmaceutical Palo Alto site. He also holds a MS in biochemistry from Peking University and BS in biochemistry from Sichuan University.